Loading
A phase 2 trial of adebrelimab, vinorelbine, cyclophosphamide and capecitabine in triple-negative breast cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, not yet recruiting.
Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer is a phase 2, randomised interventional study registered as NCT06229067 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with a registry enrolment figure of 182 participants, started 2024-01-19 and due to reach its primary completion in 2025-01-19. Interventions recorded: Adebrelimab; Vinorelbine; Cyclophosphamide (tablet); Capecitabine. Conditions listed: Breast Cancer; Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Participants with clear clinical records of metastatic triple-negative breast cancer, as specified in the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines". No results are recorded here; the registry entry is the source.
Shares Vinorelbine, Cyclophosphamide, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Adebrelimab, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Adebrelimab, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Cyclophosphamide, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Cyclophosphamide, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.